CIS Pharma at Sachs Biotech in Europe Forum in Basel
Basel, Switzerland, Wednesday, September 21, 2022 – CIS Pharma will attend the 22nd Annual Biotech in Europe Forum in Basel. Taking place during the Sachs Autumn Life Sciences Week, [...]
CIS Pharma performing pre-clinical study with radioligand targeting CD 171 with Lutetium 177
Bubendorf, Switzerland, Tuesday, September 18 - CIS Pharma has initiated the production of an antibody-radionuclide conjugate, ARC, based on its humanized lead anti-CD171 antibody. The ARC Lutetium-177, at a radionuclide-to-antibody [...]
CIS Pharma performing pre-clinical study with ADC targeting CD 171 with monomethyl auristatin E
Bubendorf, Switzerland, Wednesday, September 15, 2022 - CIS Pharma has initiated the production of an antibody-drug conjugate, ADC, based on its humanized lead anti-CD171 antibody. The ADC comprises monomethyl auristatin [...]
CIS Pharma has tested successfully its lead antibody targeting CD 171 in a biodistribution study
Villigen, Switzerland, Thursday, August 18, 2022 - CIS Pharma and its partner at ETH, Zürich, the division for radiopharmaceuticals, Paul Scherrer Institute, PSI, have made significant progress in their [...]
CIS Pharma at Swiss Biotech Day in Basel
Basel, Switzerland, Monday, May 2, 2022 - CIS Pharma will attend the Swiss Biotech Day in Basel, one of the leading biotechnology conferences in Europe. The team is looking forward [...]
CIS Pharma has identified lead candidates for the development of B7H3 nanobodies targeting CD 276
Bubendorf, Switzerland, Monday, March 14, 2022 - CIS Pharmas has identified two lead candidates for the development of the first nanobody polymer conjugate targeting B7H3, CD 276. Based on [...]
Preclinical development of a novel radiopharmaceutical bioconjugate with the potential to cross the blood brain barrier
Bubendorf, Switzerland, Friday, December 3, 2021 – CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to [...]
Feasibility study initiated to develop a novel drug carrier to deliver oligonucleotides, ASO and siRNA
Bubendorf, Switzerland, Monday, November 22, 2021 – CIS Pharma has initiated a feasibility study to develop a novel carrier to conjugate ASO and siRNA for targeted delivery, in collaboration with [...]
Preclinical development of lead antibody-radionuclide conjugate targeting L1CAM to treat cancer patients resistant to chemotherapy
Bubendorf, Switzerland, Monday, May 31, 2021 - CIS Pharma and the Paul Scherrer Institute of ETH were granted a two-year research program by Innosuisse to develop an antibody-radionuclide conjugate, ARC, [...]
Development of nanobody conjugate to cross blood brain barrier and treat brain tumors
Bubendorf, Switzerland, Thursday, May 20, 2021 - CIS Pharma has started the development of a nanobody against a novel tumor target. The antigen is homogeneously overexpressed in various forms of [...]